Rutika Mehta, MD, MPH, discusses perioperative durvalumab plus FLOT and first-line options for patients with low or negative PD-L1 gastroesophageal cancer.
|Videos|June 1, 2017
Use of SBRT in Treating Pancreatic Cancer
Author(s)Sarah E. Hoffe, MD
This video highlights the evolution of stereotactic body radiation therapy in the treatment of pancreatic cancer.
Advertisement
In this video, Sarah E. Hoffe, MD, of the Moffitt Cancer Center in Tampa, Florida, discusses the evolution of stereotactic body radiation therapy (SBRT) for the treatment of pancreatic cancer.
Hoffe also highlights a recent study
Advertisement
Related to this article
Sunnie Kim, MD, discusses postoperative management for patients without a pathologic response after neoadjuvant durvalumab plus FLOT.
Rutika Mehta, MD, MPH, explains how she sequences MSI, HER2, claudin 18.2, and PD-L1 testing when tissue is limited in gastroesophageal cancer.
A bispecific in biliary tract cancer, dostarlimab organ preservation in rectal cancer, and KRAS G12D data in pancreatic cancer stood out at ESMO 2026.
Futibatinib, pemigatinib, and lirafugratinib showed similar response rates and progression-free survival at first FGFR inhibitor exposure in biliary tract cancers with FGFR alterations.
A post hoc ReFocus analysis found prior immune checkpoint inhibitor exposure raised the risk of mucocutaneous AEs with lirafugratinib.
More than two-thirds of patients with mismatch repair–deficient locally advanced rectal cancer achieved a clinical complete response with dostarlimab alone.
Data from the phase 3 HARMONi-GI1 trial support first-line ivonescimab plus chemotherapy as a new standard of care in advanced biliary tract cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Blood mRNA Model Predicts Castration Resistance in Metastatic Prostate Cancer
2
Prioritizing Biomarker Testing to Conserve Tissue in Gastroesophageal Cancer
3
Triplet Therapy Emerges as a First-Line Option in BRAF V600–Mutant Melanoma
4
Choosing Between Triplet Therapy and Immunotherapy in BRAF-Mutant Melanoma
5